menu search

AZN / Could This Rare-Disease Drug Candidate Become a Blockbuster?

Could This Rare-Disease Drug Candidate Become a Blockbuster?
AstraZeneca and Ionis recently shared promising phase 3 clinical trials for eplontersen. If approved, the drug candidate could top $1 billion in annual sales -- split between the two companies. Read More
Posted: Apr 19 2023, 09:15
Author Name: The Motley Fool
Views: 103078

AZN News  

AstraZeneca inks gene editing deal that could end up costing it $2.5bn

By Proactive Investors
November 1, 2023

AstraZeneca inks gene editing deal that could end up costing it $2.5bn

AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) more_horizontal

AstraZeneca signs drug development deal with biotech Cellectis

By Reuters
November 1, 2023

AstraZeneca signs drug development deal with biotech Cellectis

AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to spee more_horizontal

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

By Zacks Investment Research
October 31, 2023

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day. more_horizontal

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

By Zacks Investment Research
October 30, 2023

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact th more_horizontal

3 No-Brainer Stocks to Buy for Under $100 Right Now

By The Motley Fool
October 28, 2023

3 No-Brainer Stocks to Buy for Under $100 Right Now

AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19. more_horizontal

These healthcare stocks should come to life as boomers live their golden years

By Market Watch
October 25, 2023

These healthcare stocks should come to life as boomers live their golden years

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healt more_horizontal

Barclays and AstraZeneca up staff pay as Real Living Wage increases

By Proactive Investors
October 24, 2023

Barclays and AstraZeneca up staff pay as Real Living Wage increases

Employers which pay staff the Real Living Wage (RLW) will have to find an extra 10% after it was increased to £12 in the UK and £13.10 in London on more_horizontal

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

By Market Watch
October 24, 2023

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccine

AstraZeneca PLC AZN, -1.22% AZN, +1.45% said Tuesday the U.S. Food and Drug Administration has accepted its application for approval of a self-adminis more_horizontal


Search within

Pages Search Results: